
Shares of drug developer Zymeworks ZYME.O rise 2.3% to $23.70
Co says it has appointed investment industry veteran Brian Cherry to its board of directors
Cherry previously served as managing partner at private equity firm Oak Hill Capital - ZYME
Adds Dr. Sabeen Mekan to become Chief Medical Officer on February 1, replacing Dr. Jeff Smith
Mark Hollywood promoted to EVP and COO; five new VPs named to strengthen leadership team - ZYME
Says Chief Financial and Business Officer Leone Patterson and General Counsel Daniel Dex to exit in Q1
CEO Kenneth Galbraith to serve as acting CFO until successor is appointed - ZYME
As of last close, stock up ~80% over the past year